This episode focuses on cytotoxic chemotherapy as the pharmacology of turning speed against itself. Cytotoxic drugs do not recognise cancer by identity, but by behaviour-targeting cells that divide rapidly, repair poorly, and fail to pause. We explore antimetabolites, alkylating agents, platinum compounds, antitumour antibiotics, and mitotic inhibitors to understand why efficacy and toxicity are inseparable, and why supportive care is not optional but integral. The clinical lens is realism: knowing what these drugs can achieve, and what they inevitably cost.

Key takeaways to stabilise understanding:

* Growth as vulnerability: why cell division creates therapeutic opportunity.

* Phase specificity: cell-cycle–specific vs non-specific agents.

* Dose-limiting toxicities: marrow, gut, hair, and fertility.

* Resistance patterns: efflux, DNA repair, and altered targets.

* Supportive strategy: antiemetics, growth factors, timing, and recovery windows.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe